ASX Healthcare Spotlight: Could Oneview Healthcare (ASX:ONE) Be a September 2026 Stock to Watch?

Aditi Sarkar

14 September 2026 04:15 PM AEST

ASX Healthcare Spotlight: Could Oneview Healthcare (ASX:ONE) Be a September 2026 Stock to Watch?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Hospital software is a slow Business to build and a durable one to own, which is roughly the bet Oneview Healthcare (ASX:ONE) has been asking investors to make. The Dublin-headquartered company sells patient and care team experience software into hospitals and health systems, primarily in the United States, and has steadily widened both its product set and its Revenue base.

It reported half-year accounts in late August 2026 and carried a Market Capitalisation of about A$143 million as at 11 September 2026. For an ASX-listed healthcare technology name of this size, the question is whether revenue growth can outrun a persistent operating loss.

Latest Development

Oneview lodged its Half Yearly Report and Accounts together with a Half Year 2026 Investor Presentation on 26 August 2026, alongside an update to its continuous disclosure policy. Those documents are the most current window into trading conditions. In early September there was also index-related news: a 4 September 2026 announcement referenced the S&P Dow Jones Indices September 2026 quarterly rebalance, and an application for Quotation of securities was lodged on 1 September.

Company Overview

Oneview supplies a cloud-native platform used at the hospital bedside. On the patient side, the software delivers education, entertainment, meal ordering and communication through in-room screens. On the clinical side, it provides tools intended to reduce administrative load for nursing and care teams.

The company is incorporated in Ireland and has been ASX-listed since March 2016. Its commercial model centres on multi-year contracts with health systems, so new hospital wins tend to translate into Recurring Revenue over time rather than one-off sales.

Recent Developments

Product expansion has been the consistent theme through 2026. In February the company introduced Ovie, positioned as a unified digital care assistant acting as an orchestration layer for patient requests and routing within hospital operations.

In May 2026 Oneview announced Bedside Hub, described as a new revenue channel that hosts Epic's MyChart Bedside TV experience on healthcare-grade hardware as a fully managed service. Given Epic's footprint across large United States health systems, that integration broadens the set of hospitals Oneview can address. In December 2025 the company announced a Partnership with Peterson Health, deploying the platform across inpatient rooms in Kerrville, Texas.

Financial and Operational Position

For the year ended December 2025, Oneview reported revenue of about A$21.0 million, up from roughly A$16.6 million in the year to December 2024. Losses remained substantial, with EBITDA of about negative A$18.4 million in 2025 against negative A$17.1 million in 2024, and net loss after tax of approximately A$22.1 million versus A$18.1 million.

The company pays no dividend. Revenue growth of roughly a quarter year on year has so far been accompanied by a widening absolute loss, which places the emphasis on Operating Leverage in future periods.

What Investors May Watch Next

Contracted revenue disclosures and new health system wins are the most direct indicators to follow, particularly any driven by the Epic MyChart Bedside TV integration. Investors may also be watching commercial traction for Ovie, the cash position and funding runway disclosed in periodic reports, and whether gross Margin improves as more revenue shifts towards managed software services.

Risks

Oneview remains loss-making and reliant on Capital Markets or improved cash generation to fund growth. Hospital procurement cycles are long and capital budgets can be deferred. Revenue is concentrated in the United States, creating currency and policy exposure, and the company depends on integrations with third-party electronic medical record vendors.

Key Takeaways

Oneview enters the final months of 2026 with a broader product suite, a meaningful integration with one of the dominant United States electronic medical record platforms, and revenue moving in the right direction. The counterweight is an operating loss that has not yet narrowed. Whether Oneview earns a place on watchlists this September may come down to what its half-year accounts show about the pace at which growth is converting into improved economics.

FAQs

Q: What is the ASX ticker for Oneview Healthcare PLC?

A: Oneview Healthcare PLC trades under the ticker (ASX:ONE).

Q: Why is Oneview Healthcare PLC in focus?

A: The article explains the company developments, operating context and key factors relevant to its current ASX profile.

Q: What should readers monitor next for Oneview Healthcare PLC?

A: Readers can monitor company announcements, operational updates and financial disclosures for further developments.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.